BioLife Solutions Q4 revenue rises 20% yr/yr

BioLife Solutions

26/02/2026 21:37

Overview

Cell processing tools maker's Q4 2025 revenue up 20% yr/yr

Adjusted EBITDA for Q4 2025 rose to $6.9 mln, with margin improving to 28% from 18% last year

Company expects 2026 revenue growth of 17%-20% over 2025

Outlook

BioLife expects 2026 revenue between $112.5 mln and $115 mln, up 17%-20% from 2025

Company anticipates operating margin expansion and improved adjusted EBITDA in 2026

BioLife sees full-year GAAP profitability in 2026

Result Drivers

BIOPRESERVATION MEDIA - Co's revenue growth driven by strong performance in biopreservation media franchise

CGT MARKET EXPANSION - Growth in CGT market, including new therapy approvals and geographic expansions, expected to drive demand

Company press release: ID:nPnbS05NZa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted Gross Margin
64.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for BioLife Solutions Inc is $32.00, about 42.4% above its February 25 closing price of $22.47

The stock recently traded at 250 times the next 12-month earnings vs. a P/E of 1,470 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)